Seoulin Bioscience Co.Ltd (038070) — Cash Flow-to-Debt Ratio
Seoulin Bioscience Co.Ltd (038070) has a Cash Flow-to-Debt Ratio of 0.02x as of December 2025, meaning its operating cash flow of ₩631.76 Million could theoretically repay 0% of its total liabilities (₩32.75 Billion) in one year. Explore 038070 long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Seoulin Bioscience Co.Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Seoulin Bioscience Co.Ltd across 13 annual periods. Also explore 038070 asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Seoulin Bioscience Co.Ltd (2013–2025)
Year-by-year debt coverage analysis for Seoulin Bioscience Co.Ltd. For market capitalisation and broader financial context, see 038070 market cap.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.15x | ₩4.76 Billion | ₩32.75 Billion | ▲ +155.6% |
| 2024 | -0.26x | ₩-4.61 Billion | ₩17.63 Billion | ▼ -972.3% |
| 2023 | 0.03x | ₩930.57 Million | ₩31.04 Billion | ▲ +135.2% |
| 2022 | -0.09x | ₩-4.36 Billion | ₩51.08 Billion | ▼ -159.0% |
| 2021 | 0.14x | ₩8.92 Billion | ₩61.71 Billion | ▼ -28.1% |
| 2020 | 0.20x | ₩3.68 Billion | ₩18.33 Billion | ▼ -42.3% |
| 2019 | 0.35x | ₩7.32 Billion | ₩21.00 Billion | ▲ +45.3% |
| 2018 | 0.24x | ₩4.17 Billion | ₩17.39 Billion | ▲ +260.4% |
| 2017 | 0.07x | ₩1.30 Billion | ₩19.54 Billion | ▼ -56.8% |
| 2016 | 0.15x | ₩2.76 Billion | ₩17.87 Billion | ▼ -22.1% |
| 2015 | 0.20x | ₩4.12 Billion | ₩20.80 Billion | ▲ +27.0% |
| 2014 | 0.16x | ₩2.74 Billion | ₩17.57 Billion | ▼ -40.6% |
| 2013 | 0.26x | ₩4.94 Billion | ₩18.82 Billion | — |